These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 21933751

  • 1. Prevention of CNS relapse in diffuse large B-cell lymphoma.
    Kridel R, Dietrich PY.
    Lancet Oncol; 2011 Dec; 12(13):1258-66. PubMed ID: 21933751
    [Abstract] [Full Text] [Related]

  • 2. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
    Ferreri AJ, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, Foppoli M, Vignati A, Scarfò L, Sassone M, Govi S, Caligaris-Cappio F.
    Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
    [Abstract] [Full Text] [Related]

  • 3. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
    Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, Zhang L, Buckstein R.
    Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
    [Abstract] [Full Text] [Related]

  • 4. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
    Tai WM, Chung J, Tang PL, Koo YX, Hou X, Tay KW, Quek R, Tao M, Lim ST.
    Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
    [Abstract] [Full Text] [Related]

  • 5. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
    Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H, Lopez-Guillermo A, Martinelli G, Merli F, Novero D, Orsucci L, Pavone V, Ricardi U, Storti S, Gospodarowicz MK, Cavalli F, Sarris AH, Zucca E.
    J Clin Oncol; 2011 Jul 10; 29(20):2766-72. PubMed ID: 21646602
    [Abstract] [Full Text] [Related]

  • 6. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
    Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, Muzikansky A, Hochberg EP.
    Cancer; 2010 Sep 15; 116(18):4283-90. PubMed ID: 20564149
    [Abstract] [Full Text] [Related]

  • 7. Prophylactic CNS directed therapy in systemic diffuse large B cell lymphoma.
    Ghose A, Kundu R, Latif T.
    Crit Rev Oncol Hematol; 2014 Sep 15; 91(3):292-303. PubMed ID: 24698003
    [Abstract] [Full Text] [Related]

  • 8. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
    Kansara R.
    Curr Treat Options Oncol; 2018 Sep 10; 19(11):52. PubMed ID: 30203318
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.
    Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA.
    Cancer; 2012 Jun 01; 118(11):2944-51. PubMed ID: 22006274
    [Abstract] [Full Text] [Related]

  • 11. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era.
    Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Yano T, Okamoto R, Kikuchi A, Tamura K, Sato K, Sunami K, Shibayama H, Takimoto R, Ohshima R, Hatta Y, Moriuchi Y, Kinoshita T, Yamamoto M, Numata A, Ishigatsubo Y, Takeuchi K.
    Cancer Sci; 2012 Feb 01; 103(2):245-51. PubMed ID: 22044593
    [Abstract] [Full Text] [Related]

  • 12. [Isolated central nervous system relapse of diffuse large B-cell lymphoma in the era of immunochemotherapy].
    Krmek DZ, Ljubić N, Vrbanić L.
    Acta Med Croatica; 2012 Dec 01; 66(5):403-7. PubMed ID: 23814970
    [Abstract] [Full Text] [Related]

  • 13. [Treatment strategy for central nervous system involvement in intravascular large B-cell lymphoma].
    Shimada K.
    Brain Nerve; 2011 May 01; 63(5):467-72. PubMed ID: 21515926
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prevention of central nervous system relapses in diffuse large B-cell lymphoma: which patients and how?
    Korfel A.
    Curr Opin Oncol; 2011 Sep 01; 23(5):436-40. PubMed ID: 21760506
    [Abstract] [Full Text] [Related]

  • 19. Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era.
    Fletcher CD, Kahl BS.
    Leuk Lymphoma; 2014 Oct 01; 55(10):2228-40. PubMed ID: 24286262
    [Abstract] [Full Text] [Related]

  • 20. Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma.
    Mannisto S, Vähämurto P, Pollari M, Clausen MR, Jyrkkiö S, Kellokumpu-Lehtinen PL, Kovanen P, Karjalainen-Lindsberg ML, d'Amore F, Leppä S.
    Eur J Cancer; 2019 Jul 01; 115():27-36. PubMed ID: 31082690
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.